Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Electrophysiological characterization of sleep/wake, activity and the response to caffeine in adult cynomolgus macaques.

Goonawardena AV, Morairty SR, Orellana GA, Willoughby AR, Wallace TL, Kilduff TS.

Neurobiol Sleep Circadian Rhythms. 2018 Aug 22;6:9-23. doi: 10.1016/j.nbscr.2018.08.001. eCollection 2019 Jan.

2.

The Nociceptive Opioid Peptide Receptor System and Posttraumatic Stress Disorder: An Enigma Wrapped Around a Conundrum.

Martin WJ, Wallace TL.

Biol Psychiatry. 2019 Jun 15;85(12):986-988. doi: 10.1016/j.biopsych.2019.04.017. No abstract available.

PMID:
31171112
3.

Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques.

Goonawardena AV, Morairty SR, Dell R, Orellana GA, Hoener MC, Wallace TL, Kilduff TS.

Neuropsychopharmacology. 2019 Jul;44(8):1485-1493. doi: 10.1038/s41386-019-0386-8. Epub 2019 Apr 6.

PMID:
30954024
4.
5.

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy.

Crane A, Brubaker WD, Johansson JU, Trigunaite A, Ceballos J, Bradt B, Glavis-Bloom C, Wallace TL, Tenner AJ, Rogers J.

Alzheimers Dement. 2018 Feb;14(2):243-252. doi: 10.1016/j.jalz.2017.04.015. Epub 2017 Jul 26.

6.

Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.

Brubaker WD, Crane A, Johansson JU, Yen K, Garfinkel K, Mastroeni D, Asok P, Bradt B, Sabbagh M, Wallace TL, Glavis-Bloom C, Tenner AJ, Rogers J.

Alzheimers Dement. 2017 Dec;13(12):1397-1409. doi: 10.1016/j.jalz.2017.03.010. Epub 2017 May 2.

7.

Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia.

Wallace TL, Bertrand D.

Int Rev Neurobiol. 2015;124:79-111. doi: 10.1016/bs.irn.2015.08.003. Epub 2015 Sep 26. Review.

PMID:
26472526
8.

Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.

Goonawardena AV, Heiss J, Glavis-Bloom C, Trube G, Borroni E, Alberati D, Wallace TL.

Neuropsychopharmacology. 2016 Apr;41(5):1319-28. doi: 10.1038/npp.2015.281. Epub 2015 Sep 10.

9.

Animal paradigms to assess cognition with translation to humans.

Wallace TL, Ballard TM, Glavis-Bloom C.

Handb Exp Pharmacol. 2015;228:27-57. doi: 10.1007/978-3-319-16522-6_2. Review.

PMID:
25977079
10.

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.

Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.

JAMA Psychiatry. 2014 Jun;71(6):637-46. doi: 10.1001/jamapsychiatry.2014.163.

PMID:
24696094
11.

Measuring emotion socialization in schools.

Horner CG, Wallace TL.

J Sch Health. 2013 Oct;83(10):697-703. doi: 10.1111/josh.12083.

PMID:
24020683
12.

Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex.

Wallace TL, Bertrand D.

Biochem Pharmacol. 2013 Jun 15;85(12):1713-20. doi: 10.1016/j.bcp.2013.04.001. Epub 2013 Apr 26. Review.

PMID:
23628449
13.

Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia.

Wallace TL, Bertrand D.

Expert Opin Ther Targets. 2013 Feb;17(2):139-55. doi: 10.1517/14728222.2013.736498. Epub 2012 Dec 11. Review.

PMID:
23231385
14.

Consideration of species differences in developing novel molecules as cognition enhancers.

Young JW, Jentsch JD, Bussey TJ, Wallace TL, Hutcheson DM.

Neurosci Biobehav Rev. 2013 Nov;37(9 Pt B):2181-93. doi: 10.1016/j.neubiorev.2012.10.002. Epub 2012 Oct 12. Review.

15.

Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.

Revel FG, Moreau JL, Gainetdinov RR, Ferragud A, Velázquez-Sánchez C, Sotnikova TD, Morairty SR, Harmeier A, Groebke Zbinden K, Norcross RD, Bradaia A, Kilduff TS, Biemans B, Pouzet B, Caron MG, Canales JJ, Wallace TL, Wettstein JG, Hoener MC.

Biol Psychiatry. 2012 Dec 1;72(11):934-42. doi: 10.1016/j.biopsych.2012.05.014. Epub 2012 Jun 16.

PMID:
22705041
16.

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.

Revel FG, Moreau JL, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross RD, Tuerck D, Bruns A, Morairty SR, Kilduff TS, Wallace TL, Risterucci C, Wettstein JG, Hoener MC.

Mol Psychiatry. 2013 May;18(5):543-56. doi: 10.1038/mp.2012.57. Epub 2012 May 29.

PMID:
22641180
17.

Depicting the logic of three evaluation theories.

Hansen M, Alkin MC, Wallace TL.

Eval Program Plann. 2013 Jun;38:34-43. doi: 10.1016/j.evalprogplan.2012.03.012. Epub 2012 Mar 10.

PMID:
22465702
18.

Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease.

Wallace TL, Porter RH.

Biochem Pharmacol. 2011 Oct 15;82(8):891-903. doi: 10.1016/j.bcp.2011.06.034. Epub 2011 Jul 2. Review.

PMID:
21741954
19.

Drug targets for cognitive enhancement in neuropsychiatric disorders.

Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG.

Pharmacol Biochem Behav. 2011 Aug;99(2):130-45. doi: 10.1016/j.pbb.2011.03.022. Epub 2011 Apr 1. Review.

PMID:
21463652
20.

Enhanced long-term depression and impaired reversal learning in phosphodiesterase 4B-knockout (PDE4B-/-) mice.

Rutten K, Wallace TL, Works M, Prickaerts J, Blokland A, Novak TJ, Santarelli L, Misner DL.

Neuropharmacology. 2011 Jul-Aug;61(1-2):138-47. doi: 10.1016/j.neuropharm.2011.03.020. Epub 2011 Mar 31.

PMID:
21458469
21.

RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.

Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA.

J Pharmacol Exp Ther. 2011 Jan;336(1):242-53. doi: 10.1124/jpet.110.171892. Epub 2010 Oct 19.

PMID:
20959364
22.

Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice.

Rutten K, Misner DL, Works M, Blokland A, Novak TJ, Santarelli L, Wallace TL.

Eur J Neurosci. 2008 Aug;28(3):625-32. doi: 10.1111/j.1460-9568.2008.06349.x.

PMID:
18702734
23.

[In vitro activity of a liposomal nystatin formulation (Nyotran) against Cryptococcus neoformans].

Alonso-Vargas R, González-Alvarez L, Ruesga MT, Carrillo-Muñoz AJ, Martín-Mazuelos E, Wallace TL, Cossum PA, Pontón J, Quindós G.

Rev Iberoam Micol. 2000 Sep;17(3):90-2. Spanish.

24.
25.

Developmental D-methamphetamine treatment selectively induces spatial navigation impairments in reference memory in the Morris water maze while sparing working memory.

Williams MT, Morford LL, Wood SL, Wallace TL, Fukumura M, Broening HW, Vorhees CV.

Synapse. 2003 Jun 1;48(3):138-48.

PMID:
12645039
26.

Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress.

Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, Wallace TL, Broening HW, Moran MS, Vorhees CV.

Brain Res. 2003 Apr 4;968(1):89-101.

PMID:
12644267
27.

Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain.

Wallace TL, Vorhees CV, Zemlan FP, Gudelsky GA.

Neuroscience. 2003;116(4):1063-8.

PMID:
12617947
28.

Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.

Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, Chen J, Neve R, Nestler EJ, Duman RS.

J Neurosci. 2002 Dec 15;22(24):10883-90.

29.
30.
31.

Neurotoxic regimen of methamphetamine produces evidence of behavioral sensitization in the rat.

Wallace TL, Gudelsky GA, Vorhees CV.

Synapse. 2001 Jan;39(1):1-7.

PMID:
11071703
32.

In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens.

Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, Rubio M, Wallace TL, Cossum PA, Martín-Mazuelos E, Cisterna R, Pontón J.

Eur J Clin Microbiol Infect Dis. 2000 Aug;19(8):645-8. No abstract available.

PMID:
11014634
33.

The reproductive and developmental toxicity of the antifungal drug Nyotran (liposomal nystatin) in rats and rabbits.

Larson JL, Wallace TL, Tyl RW, Marr MC, Myers CB, Cossum PA.

Toxicol Sci. 2000 Feb;53(2):421-9.

PMID:
10696790
34.

Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide.

Wallace TL, Gamba-Vitalo C, Loveday KS, Cossum PA.

Toxicol Sci. 2000 Jan;53(1):63-70.

PMID:
10653522
35.
36.
38.

Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.

Jacobsen EJ, Mitchell MA, Hendges SK, Belonga KL, Skaletzky LL, Stelzer LS, Lindberg TJ, Fritzen EL, Schostarez HJ, O'Sullivan TJ, Maggiora LL, Stuchly CW, Laborde AL, Kubicek MF, Poorman RA, Beck JM, Miller HR, Petzold GL, Scott PS, Truesdell SE, Wallace TL, Wilks JW, Fisher C, Goodman LV, Kaytes PS, et al.

J Med Chem. 1999 May 6;42(9):1525-36.

PMID:
10229623
40.

Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW.

Antimicrob Agents Chemother. 1998 Jun;42(6):1412-6.

41.

Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.

Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E.

Antimicrob Agents Chemother. 1997 Oct;41(10):2238-43.

42.

Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single- and multiple-dose intravenous administration to rats.

Wallace TL, Bazemore SA, Holm K, Markham PM, Shea JP, Chaudhary N, Cossum PA.

J Pharmacol Exp Ther. 1997 Mar;280(3):1480-8.

PMID:
9067338
43.
44.
45.

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.

Ojwang JO, Buckheit RW, Pommier Y, Mazumder A, De Vreese K, Esté JA, Reymen D, Pallansch LA, Lackman-Smith C, Wallace TL, et al.

Antimicrob Agents Chemother. 1995 Nov;39(11):2426-35.

46.

The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism.

Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, Petzold G, Mitchell M, Ledbetter S, Poorman R.

Cancer Chemother Pharmacol. 1995;36(5):418-24. Erratum in: Cancer Chemother Pharmacol 1995;37(1-2):194.

PMID:
7543375
47.

Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.

Li LH, DeKoning TF, Kelly RC, Krueger WC, McGovren JP, Padbury GE, Petzold GL, Wallace TL, Ouding RJ, Prairie MD, et al.

Cancer Res. 1992 Sep 15;52(18):4904-13.

48.

Adozelesin, a potent new alkylating agent: cell-killing kinetics and cell-cycle effects.

Bhuyan BK, Smith KS, Adams EG, Wallace TL, Von Hoff DD, Li LH.

Cancer Chemother Pharmacol. 1992;30(5):348-54.

PMID:
1505072
49.

Cytotoxicity of tetraplatin and cisplatin for human and rodent cell lines cultured as monolayers and multicellular spheroids.

Bhuyan BK, Folz SJ, DeZwaan J, Northcott SE, Alberts DS, Garcia D, Wallace TL, Li LH.

Cancer Commun. 1991 Feb;3(2):53-9.

PMID:
1995028

Supplemental Content

Loading ...
Support Center